Erythropoietin receptor is expressed in meningiomas and lower levels are associated with tumour recurrence.

摘要: Aims: The Epo-EpoR pathway plays a role in tumour growth, metastasis and treatment resistance is potential target oncological treatment. As the EpoR status human meningiomas unknown, our aim was to characterize expression these tumours. Methods: We examined 131 meningioma samples of all WHO grades from 116 patients by immunohistochemistry for EpoR. Among these, 25 showed brain invasion 29 had further recurrence. A group 20 without recurrence served as controls. In 12 cases we were able compare both primary following recurrent presence confirmed RT-PCR Western blot. Results: expressed meningiomas. Statistical analysis revealed that mean levels significantly lower tumours with known compared recurrence-free control group. Additional matched pair individual no significant differences between No correlation grade, age, sex or detected. Using specific primer pairs RT-PCR, detect three isoforms EpoR: full-length isoform EpoR-F, truncated EpoR-T soluble EpoR-S. Conclusions: Our results demonstrate Lower might be useful marker higher risk, but studies are needed clarify influence on recurrences different isoforms.